Polyphor Ltd
Edit

Polyphor Ltd

https://www.polyphor.com/
Last activity: 30.12.2021
Active
Categories: BioTechDevelopmentDrugFinTechITMedTechProductSpecialty
We aim to bring novel antibiotics and medicines for high medical needs to patients. Polyphor’s goal is to be the leader in the development of novel antibiotics and other efficacious therapies against specialty diseases with high medical needs.

Polyphor was founded in 1996 and is a clinical stage, privately held Swiss specialty pharma company, based in Allschwil near Basel. It focuses on the development of macrocycle drugs that address antibiotic resistance and severe respiratory diseases.
Likes
14
Followers
3.63K
Mentions
39
Location: United States, Indiana, York
Employees: 51-200
Phone: +41 61 567 16 00
Total raised: $39.8M
Founded date: 1996
Facebook
LinkedIn
Email

Investors 1

DateNameWebsite
-CARB-Xcarb-x.org

Funding Rounds 1

DateSeriesAmountInvestors
16.04.2017-$39.8M-

Mentions in press and media 39

DateTitleDescription
30.12.2021Polyphor closes merger with EnBiotix and is renamed SpexisEQS-Ad-hoc: Polyphor AG / Key word(s): Merger Polyphor closes merger with EnBiotix and is renamed Spexis 30-Dec-2021 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content ...
29.12.2021Polyphor to inform about the financing of its merger partner EnBiotixEQS-Ad-hoc: Polyphor AG / Key word(s): Merger/Financing Polyphor to inform about the financing of its merger partner EnBiotix 29-Dec-2021 / 07:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely respons...
02.09.2021After setback, Polyphor opts for a mergerPolyphor and Enbiotix have signed a merger agreement pursuant to which Polyphor acquires all of the outstanding capital stock of EnBiotix in exchange for shares of Polyphor common stock. Upon completion of the merger, former EnBiotix equity...
16.07.2021Nas­daq rings in Jonathan Lim's next can­cer play, Pfiz­er-backed start­up and Har­vard spin­out with col­lec­tive $534M raise un­der their beltsEd­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here. IPOs are boom­ing in 2021, and com­pa­nies are go­ing pub­lic ear­li­er than ever. About 45% of IPOs of­fered in th...
16.07.2021Alex­ion touts new PhI­II da­ta of Soliris suc­ces­sor as planned As­traZeneca takeover loomsA lit­tle less than a week be­fore As­traZeneca’s takeover of Alex­ion is ex­pect­ed to be com­plet­ed, the rare dis­ease biotech of­fered up a cut of da­ta for its Soliris suc­ces­sor. In a Phase III study for Ul­tomiris look­ing at adults...
16.07.2021Eli Lil­ly part­ner Ab­Cellera finds a CBO in the face of bam­lanivimab strug­gles; Fi­bro­Gen's next CSO walks in­to rox­adu­s­tat re­buffNeil Berkley → Covid-19 vari­ants have marred the ef­fec­tive­ness of Eli Lil­ly and Ab­Cellera’s bam­lanivimab to such an ex­tent that the US gov­ern­ment stopped us­ing the mon­o­clon­al an­ti­body in March, fol­lowed by a sim­i­lar halt ...
16.07.2021Celu­lar­i­ty emerges from SPAC merg­er dou­bled down on cell ther­a­pies as Bob Hariri down­grades ill-fat­ed Covid-19 pro­gramIt took a few months longer than ex­pect­ed, but Bob Hariri has fi­nal­ly guid­ed Celu­lar­i­ty and its pla­cen­tal-de­rived cells to Wall Street. Merg­ing with GX Ac­qui­si­tion Corp gives Celu­lar­i­ty $138 mil­lion to work with as Hariri...
16.07.2021Polyphor ax­es staff as cash and op­tions dwin­dlePolyphor’s re­struc­tur­ing is be­gin­ning. The Swiss biotech, once a dar­ling of the coun­try’s pub­lic mar­kets, an­nounced that it was lay­ing off “up to” 29 em­ploy­ees af­ter its Phase III tri­al for its lead can­cer drug failed last m...
16.07.2021Pfiz­er set­tles EpiPen price hike law­suits for $345MPfiz­er has agreed to pay $345 mil­lion as part of a set­tle­ment re­lat­ed to a 5-year-old law­suit over the com­pa­ny’s price hikes on the life­sav­ing EpiPen. Plain­tiffs across the coun­try raised con­cerns over the price of the au­toin...
16.07.2021JAK in­hibitor PDU­FA dates ex­tend­ed again as safe­ty re­view con­tin­ues; Stem­son se­cures $15M to cure hair lossTwo more sup­ple­men­tal new drug ap­pli­ca­tions have been de­layed again — this time from Ab­b­Vie, and the part­ners Eli Lil­ly and In­cyte — as the FDA con­tin­ues its on­go­ing safe­ty as­sess­ment of the class of drugs known as JAK in...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In